What we do

Autolus is at the forefront of a revolution in cancer treatment. Chimeric Antigen Receptor (CAR) T-cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential to offer a cure.

Autolus is a leader in T-cell programming and manufacturing technology. Working in partnership with physicians and other healthcare providers, we extract immune cells from patients, equip them with a receptor that targets the cancer cell and infuse them back into the patient in order to combat cancer more effectively.

Who we are

Autolus is a privately held biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out and established as an independent company by University College London in 2014.

Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to successfully manufacture, develop and commercialise T-cell therapies.

Autolus is committed to bringing life-changing treatments to cancer patients by reprogramming their own T-cells to more effectively combat the treatment of haematological malignancies and solid tumours.

Executive Team Board of Directors


Autolus collaborates with leading academic institutions and industry partners to develop and deliver transformative T-cell immunotherapy products to patients.

We are actively exploring partners with complementary technologies and capabilities.

To explore a partnership with Autolus, please contact our business development team.